frequently asked / cited
PT-141 (bremelanotide): frequently asked questions
Direct answers drawn from the published trials and the FDA label — what PT-141 is, how it works, what it is approved for, and where it stays off-label.
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the research designation for bremelanotide, the international nonproprietary name (INN) of this melanocortin receptor agonist [6]. "PT-141" is the development code and "bremelanotide" the official drug name; both refer to the same molecule carried on the FDA-approved injection.
What is bremelanotide?
Bremelanotide is a synthetic cyclic heptapeptide melanocortin (MC3R/MC4R) agonist. The FDA approved it in June 2019 as a subcutaneous injection for acquired, generalized HSDD in premenopausal women [3][6]. It acts centrally on brain circuits of sexual desire rather than on blood flow [1].
What is the approved bremelanotide dose?
Per the U.S. prescribing information, 1.75 mg subcutaneously as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than eight doses per month [7]. This is reported as a label finding only, not a protocol for any reader to follow.
Is PT-141 approved for men?
No. The FDA approval covers only HSDD in premenopausal women [3]. Use in men for erectile dysfunction is off-label, and the supporting evidence is early-phase and investigational — early intranasal erectile-response data and a Phase 2 combination program begun in 2024 [1].
Is PT-141 FDA-approved?
Yes, but narrowly. Bremelanotide injection was approved June 21, 2019 (NDA 210557) only for acquired, generalized HSDD in premenopausal women [3][6]. All other uses are off-label, and material sold as "PT-141 research chemical" sits outside the approved finished-drug product.
Is PT-141 legal in the US?
Bremelanotide is an FDA-approved prescription drug for HSDD in premenopausal women; it is not a U.S. controlled or scheduled substance [6]. Material sold as "PT-141 research chemical" is laboratory material only and is not the approved finished drug.
Can you get PT-141 through telehealth?
Bremelanotide is a prescription medication, so any legitimate access for the approved indication runs through a licensed clinician; remote sexual-medicine evaluation has been described in the telemedicine literature. This site summarizes research and does not sell, source, or facilitate access to any product.
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analogue of the hormone alpha-MSH that activates central melanocortin MC3R/MC4R receptors [1]. Its single FDA-approved use is HSDD in premenopausal women [3].
What is PT-141 peptide?
A synthetic cyclic heptapeptide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, that acts as a melanocortin receptor agonist [1]. Its cyclic lactam structure — a stabilizing ring — improves stability over the linear melanocortin peptides it descends from [1].
What does the PT-141 peptide do?
It activates central MC4R (and MC3R) receptors in hypothalamic and limbic circuits linked to sexual desire, acting on the brain's circuitry of sexual motivation rather than on vascular blood flow [1][5]. That central action is what distinguishes it from erection-focused blood-flow drugs.
What is PT-141 used for?
Its single FDA-approved use is acquired, generalized HSDD in premenopausal women [3]. It has also been studied off-label and investigationally for male erectile dysfunction [11] and was examined in early female-arousal and metabolic research [7].
How does PT-141 work?
By stimulating MC4R in hypothalamic circuits such as the medial preoptic area, thought to engage dopaminergic pathways that govern sexual desire and arousal [1][5]. This is a central mechanism, unlike the peripheral vascular action of PDE-5 inhibitors.
What receptors does PT-141 act on?
Chiefly the melanocortin 4 receptor (MC4R), with secondary MC3R agonism [1]. Activation of MC1R in the periphery underlies the hyperpigmentation reported with repeated dosing [11].
Does PT-141 work through the brain or through blood flow?
Through the brain. It acts centrally on melanocortin receptors in hypothalamic and limbic circuits of sexual motivation [1][5]. That is distinct from PDE-5 inhibitors, which act peripherally on vascular smooth muscle to support erectile blood flow.
What is a melanocortin receptor agonist?
A molecule that activates melanocortin receptors (MC1R–MC5R), the receptor family that responds to alpha-MSH [1]. PT-141 targets the central MC3R/MC4R subtypes involved in sexual desire and appetite.
Does PT-141 increase testosterone?
No. PT-141 does not act through the HPG axis and does not directly raise testosterone; it is a central melanocortin agonist [1]. The idea that it works by boosting testosterone is a common misconception.
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow; PT-141 acts centrally on melanocortin receptors that modulate sexual desire and arousal [1]. They address different parts of sexual response by different mechanisms.
What is the PT-141 dosage?
The approved label dose is 1.75 mg subcutaneously as needed (maximum one dose per 24 hours, eight per month); Phase 2 dose-finding in women studied 0.75, 1.25, and 1.75 mg [3][7]. Reported as study and label findings only.
How much PT-141 should I take?
This site reports trial and label doses as findings and recommends no dose for any individual. For the approved indication the label specifies 1.75 mg subcutaneously as needed within strict frequency limits, used only under clinician supervision [7].
How much PT-141 to inject?
The approved subcutaneous label dose is 1.75 mg per administration, no more than once per 24 hours and no more than eight times per month [7]. This is stated as a label finding, not a protocol to follow.
How do you reconstitute PT-141?
The approved finished product is a ready-to-use subcutaneous injection [7]. "Research chemical" lyophilized powder is non-approved laboratory material, and this site does not provide reconstitution instructions for self-administration.
What does PT-141 do for women?
In premenopausal women with HSDD, the RECONNECT Phase 3 trials found bremelanotide produced statistically significant but modest improvements in sexual desire and reduced desire-related distress versus placebo over 24 weeks [3].